Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)‘s stock had its “buy” rating reissued by equities researchers at Jefferies Group LLC in a research note issued on Wednesday. They presently have a $51.00 target price on the specialty pharmaceutical company’s stock. Jefferies Group LLC’s price objective would indicate a potential upside of 38.78% from the company’s current price.

Other research analysts also recently issued reports about the stock. BidaskClub raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 17th. Stifel Nicolaus reissued a “buy” rating and set a $47.00 price target (up from $36.00) on shares of Supernus Pharmaceuticals in a research note on Tuesday, July 18th. Zacks Investment Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price target on the stock in a research note on Thursday, July 13th. Cantor Fitzgerald lifted their price target on shares of Supernus Pharmaceuticals from $34.00 to $49.00 and gave the stock a “buy” rating in a research note on Wednesday, July 5th. Finally, Piper Jaffray Companies reissued a “hold” rating and set a $45.00 price target on shares of Supernus Pharmaceuticals in a research note on Friday, September 8th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $48.29.

Shares of Supernus Pharmaceuticals (SUPN) traded down 3.42% during trading on Wednesday, reaching $36.75. 2,356,464 shares of the company’s stock traded hands. Supernus Pharmaceuticals has a 52-week low of $17.25 and a 52-week high of $50.05. The company has a market cap of $1.86 billion, a price-to-earnings ratio of 18.54 and a beta of 1.30. The company’s 50-day moving average is $44.56 and its 200 day moving average is $37.95.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.24 by $0.08. The firm had revenue of $75.83 million for the quarter, compared to the consensus estimate of $68.54 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. Equities analysts forecast that Supernus Pharmaceuticals will post $1.04 EPS for the current year.

WARNING: This story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/09/20/supernus-pharmaceuticals-inc-supn-rating-reiterated-by-jefferies-group-llc.html.

In related news, VP Padmanabh P. Bhatt sold 3,735 shares of Supernus Pharmaceuticals stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $44.90, for a total value of $167,701.50. Following the transaction, the vice president now directly owns 21,209 shares of the company’s stock, valued at $952,284.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Padmanabh P. Bhatt sold 2,556 shares of Supernus Pharmaceuticals stock in a transaction on Friday, June 23rd. The stock was sold at an average price of $44.90, for a total transaction of $114,764.40. Following the completion of the transaction, the vice president now directly owns 24,944 shares in the company, valued at $1,119,985.60. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 160,000 shares of company stock worth $7,505,574. 6.70% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Sheets Smith Wealth Management purchased a new position in shares of Supernus Pharmaceuticals in the second quarter worth $378,000. Royce & Associates LP increased its stake in shares of Supernus Pharmaceuticals by 22.3% in the second quarter. Royce & Associates LP now owns 159,000 shares of the specialty pharmaceutical company’s stock worth $6,853,000 after buying an additional 29,000 shares during the period. Turner Investments LLC purchased a new position in shares of Supernus Pharmaceuticals in the first quarter worth $219,000. Neumeier Poma Investment Counsel LLC increased its stake in shares of Supernus Pharmaceuticals by 1.6% in the second quarter. Neumeier Poma Investment Counsel LLC now owns 890,740 shares of the specialty pharmaceutical company’s stock worth $38,391,000 after buying an additional 14,430 shares during the period. Finally, Bank of America Corp DE increased its stake in shares of Supernus Pharmaceuticals by 10.7% in the first quarter. Bank of America Corp DE now owns 362,952 shares of the specialty pharmaceutical company’s stock worth $11,361,000 after buying an additional 35,069 shares during the period. 95.38% of the stock is currently owned by institutional investors.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.